INDEX NAME NOT YET ASSIGNED
INDEX NAME NOT YET ASSIGNED Basic information
- Product Name:
- INDEX NAME NOT YET ASSIGNED
- Synonyms:
-
- 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1H-pyrazol-5-yl)-3-fluoro-1-naphthonitrile
- MRTX 9768
- SDMA,toxicity,glioblastoma,orally,MRTX9768,low,Inhibitor,hematological,MRTX-9768,MTAP,CDKN2A,MRTX 9768,inhibit,Histone Methyltransferase,anticancer,PRMT5-MTA
- CAS:
- 2629314-68-5
- MF:
- C24H17FN6O
- MW:
- 424.43
- Mol File:
- 2629314-68-5.mol
INDEX NAME NOT YET ASSIGNED Chemical Properties
- Density
- 1.44±0.1 g/cm3(Predicted)
- storage temp.
- -20°C, protect from light
- solubility
- DMSO : 30 mg/mL (70.68 mM; ultrasonic and warming and heat to 60°C)
- pka
- 11.36±0.40(Predicted)
INDEX NAME NOT YET ASSIGNED Usage And Synthesis
Biological Activity
MRTX9768 is a potent, orally active PRMT5 inhibitor. MRTX9768 is a synthetic lethal-based inhibitor designed to bind the PRMT5-MTA complex and selectively target MTAP/CDKN2A-deleted tumors[1]. MRTX9768 inhibits SDMA and cell proliferation in HCT116 MTAP-del cells (SDMA IC50 3 nM; prolif. IC50 11 nM) with marked selectivity over HCT116 MTAP-WT cells (SDMA IC50 544 nM; prolif. IC50 861 nM)[1]. In xenograft studies, oral administration of MRTX9768 demonstrates dose-dependent inhibition of SDMA in MTAP-del tumors[1].
References
[1]. Christopher R. et al. Fragment based discovery of MRTX9768, a synthetic lethal-based inhibitor designed to bind the PRMT5-MTA complex and selectively target MTAP/CDKN2A-deleted tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB003.
INDEX NAME NOT YET ASSIGNEDSupplier
- Tel
- 18149758185 18149758185
- sales-cpd@caerulumpharma.com
- Tel
- 021-QQ:65489617 15618227136
- Sales@ATKchemical.com
- Tel
- +1-781-999-5354 +1-00000000000
- marketing@targetmol.com
- Tel
- 17625585511
- 1580084073@qq.com
- Tel
- 18051384581
- sales@chemhifuture.com